While the company is no longer enjoying the benefit of enormous sales for its COVID treatment Veklury, Gilead is still doing very nicely, thank you very much.
Posts
Biopharma companies buying stock in one another did not used to be an unusual practice, but experts told BioSpace this is becoming less common due to greater market volatility.
Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker’s shares even though more data will be needed to confirm the treatment’s efficacy.
Gilead Sciences said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.
The companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacle platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.
The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time.
British drugmaker GSK’s HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc.
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely.
The U.S. health regulator has approved Roche Holding AG’s therapy for treating a type of rare cancer called follicular lymphoma.
The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc.’s Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.
